Navigation Links
Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting
Date:11/5/2007

mplication encountered during INTEGRILIN(R) therapy. The majority of excess major bleeding events were localized at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal and retroperitoneal bleeding were also seen more commonly with INTEGRILIN(R) compared to placebo; INTEGRILIN(R) is associated with an increase in major and minor bleeding at the site of arterial sheath placement; special care should be employed to minimize the risk of bleeding among these patients; if bleeding cannot be controlled with pressure, infusion of INTEGRILIN(R) and concomitant heparin should be stopped immediately; because INTEGRILIN(R) inhibits platelet aggregation, caution should be employed when it is used with other drugs that affect hemostatic, including thrombolytics, oral anticoagulants, NSAIDs, and dipyridamole; use with other GP IIb-IIIa inhibitors should be avoided; INTEGRILIN(R) is cleared in part by the kidney and its plasma concentrations are doubled in patients with renal disease (CrCl <50 mL/min); therefore, the infusion dose of INTEGRILIN(R) needs to be reduced to 1mcg/kg/min in these patients; INTEGRILIN(R) is contraindicated in patients who are dependent upon renal dialysis (please see dosing guidelines); caution should be exercised when administering INTEGRILIN(R) to patients with a platelet count <100,000/mm3.

Full prescribing information for INTEGRILIN(R) is available at http://www.integrilin.com.

About Schering-Plough

Schering-Plough Corporation is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 33,500 people around the world. Th
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Research and Markets ( ... "Telemedicine and Mobile Healthcare Solutions, Services, and ... report to their offering. ... terms that pertain to the use of telecommunications ... clinical/non-clinical healthcare services. They form the ecosystem that ...
(Date:3/3/2015)... RADNOR, Pa. , March 3, 2015 /PRNewswire/ ... of laboratory products, services and solutions, announced today ... England Biolabs®, Inc. (NEB®). This agreement allows VWR ... renowned technical support in the U.S. and Puerto ... to NEB,s products through VWR,s e-business platform, sales ...
(Date:3/3/2015)... BETHESDA, Md. , March 3, 2015 /PRNewswire/-- ViaCyte, Inc., ... cell-derived islet replacement therapy for the treatment of diabetes ... Eugene Brandon , Director of Strategic Relations and ... summit showcases the latest in type 1 diabetes management ... are as follows: , , , Title:   ...
Breaking Medicine Technology:Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 3VWR Announces Expansion of Distribution Agreement with New England Biolabs 2ViaCyte to Present at JDRF TypeOneNation Research Summit 2
(Date:3/4/2015)... Professionals with disabilities are eager to ... companies, according to a new Think Beyond the Label ... 235 professionals with disabilities , respondents also say they ... including ones that are geared to people with disabilities, ... ,     Online job search tools are used by ...
(Date:3/4/2015)... 04, 2015 The medical device landscape ... management forgot – or ignored or didn't know – ... market based on physician input before proceeding to design ... specifically, founders – become so enamored of an innovative ... Will physicians use the device?” says Dr. Kathryn ...
(Date:3/3/2015)... Anik Singal's Profit Academy - ... marketers has become the talk of the town ... surrounding the course's general release has garnered the ... her to review the program's content and publish ... biggest keys to success with Internet marketing is ...
(Date:3/3/2015)... March 03, 2015 On February 21st, ... the fabulous EcoLuxe Lounge, a day-long event that features ... conscious products and services. Organized by Debbie Durkin and ... film placement producer, the EcoLuxe Lounge saw many notable ... roles on General Hospital, The Flash, Star Trek: Deep ...
(Date:3/3/2015)... March 03, 2015 Findings could lead ... at UC Davis have developed and characterized a molecule ... causing them to self-destruct. This novel mechanism was found ... a usually fatal type of brain cancer – and ... , The article, to be published in the April ...
Breaking Medicine News(10 mins):Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 2Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 3Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 2Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 3Health News:Anik Singal's Profit Academy - Review Of New IM Training Program Released 2Health News:Hollywood Star Chase Masterson and Choices Recovery Discuss Substance Abuse and Treatment at 2015 Oscars 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4
... could actually be caused as a result of a defect ... after scientists have worked towards identifying important skin cancer genes ... scientists to look at thousands of genes at once, helping ... greater detail. There are over 200 different types of cancer ...
... ketoacidosis (DKA) is a life-threatening condition that frequently ... The critical factors in the treatment of DKA ... skillful fluid and electrolyte adjustment, and the initiation ... fluid volume has been achieved. Continuous low-dosage intravenous ...
... Anderson Cancer Center have found that weight gain or ... of prostrate cancer. ,The report is detailed in ... Research, corroborates findings of an earlier research that had ... Strom, Ph.D., an associate professor in the Department of ...
... Phase II study to 12 months confirm the significant effects ... patients with relapsing multiple sclerosis (MS). ,The data, ... both patient groups taking FTY720 (1.25 mg and 5 mg) ... of more than 50% during the first six months of ...
... chronic illness that requires continuing medical care and ... to reduce the risk of long-term complications//. As ... care practitioners are confronted with an ever-increasing tide ... Undiagnosed chronic kidney disease (CKD) is common in ...
... an ancient myth that coco bean can be used to treat ... limit the development of fluids that cause diarrhea//. ,The use ... 16th century by ancient South American and European cultures. Until now, ... bean or more specifically why it has been used in the ...
Cached Medicine News:Health News:Novartis MS Drug Shows Promising Results 2Health News:Novartis MS Drug Shows Promising Results 3
... simple, effective method for determining color vision ... data which can be applied to many ... set consists of four trays containing a ... that have incremental hue variation on one ...
... D15 test evaluation has a choice ... caps with automatic creation 'horse-shoe' diagrams, ... deficiency analysis, calculation of color confusion ... eye selection (OD, OS, OU) and ...
... Farnsworth D15 test is used ... color defect vs normal. Farnsworth ... which permit the patient to ... Then the box is closed ...
HRR/Amsler book combo with occluding glasses....
Medicine Products: